⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL293116 | 0.78 | — | — | |
| SCHEMBL9815124 | 0.73 | — | — | |
| SCHEMBL3195573 | 0.73 | — | — | |
| SCHEMBL3789962 | 0.73 | — | — | |
| SCHEMBL5093472 | 0.73 | — | — | |
| SCHEMBL8413483 | 0.71 | — | — | |
| SCHEMBL20197695 | 0.71 | — | — | |
| SCHEMBL2354839 | 0.71 | — | — | |
| SCHEMBL14520488 | 0.71 | — | — | |
| SCHEMBL2354840 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020041329-A1 | COMBINATION THERAPY FOR TREATING OR PREVENTING DEPRESSION OR OTHER MOOD DISEASES | YALE UNIVERSITY (US) | 2020-02-27 | — | — | WO | claimed |
| US-20090005419-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-01-01 | — | — | US | claimed |
| EP-1859278-A1 | METHOD FOR THE SCREENING OF COMPOUNDS THAT MODULATE THE INTERACTION BETWEEN MRNA AND PROTEINS AND COMPOUNDS OBTAINABLE THEREBY | Novartis AG (CH) | 2007-11-28 | — | — | EP | claimed |
| WO-2006094688-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-09-14 | — | — | WO | claimed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | claimed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | claimed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | claimed |
| US-9168255-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA L.P. (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150250789-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA L.P. | 2015-09-10 | — | — | US | disclosed |
| US-9045435-B2 | Quinazoline compounds as sodium channel blockers | PURDUE PHARMA, L.P. (US) | 2015-06-02 | — | — | US | disclosed |
| EP-2625169-B1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | PURDUE PHARMA LP (US) | 2015-03-25 | — | — | EP | disclosed |
| US-20130289044-A1 | Quinazoline Compounds as Sodium Channel Blockers | PURDUE PHARMA L.P. (US) | 2013-10-31 | — | — | US | disclosed |
| EP-2625169-A1 | QUINAZOLINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS | Purdue Pharma L.P. (US) | 2013-08-14 | — | — | EP | disclosed |
| EP-1153024-B1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| US-20020016329-A1 | 2-Amino-6-anilino-purines and their use as medicaments | NOVARTIS AG (CH) | 2002-02-07 | — | — | US | disclosed |
| EP-1153024-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | Novartis AG (CH) | 2001-11-14 | — | — | EP | disclosed |
| WO-2000049018-A1 | 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS | NOVARTIS AG (CH) | 2000-08-24 | — | — | WO | disclosed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | disclosed |